Literaturnachweis - Detailanzeige
Autor/inn/en | Engebretsen, Maria Hagen; Kildahl, Arvid Nikolai; Hoy, Iver Harald; Bakken, Trine Lise |
---|---|
Titel | Metyrosine Treatment in a Woman with Chromosome 22q11.2 Deletion Syndrome and Psychosis: A Case Study |
Quelle | In: International Journal of Developmental Disabilities, 65 (2019) 2, S.116-121 (6 Seiten)Infoseite zur Zeitschrift
PDF als Volltext |
Sprache | englisch |
Dokumenttyp | gedruckt; online; Zeitschriftenaufsatz |
ISSN | 2047-3869 |
DOI | 10.1080/20473869.2017.1401257 |
Schlagwörter | Genetic Disorders; Congenital Impairments; Females; Psychosis; Drug Therapy; Intellectual Disability; Aggression; Milieu Therapy; Adults |
Abstract | Background: People with 22q11.2 deletion syndrome (DS) are assumed to be especially vulnerable to developing mental illness such as psychosis. Aim: The study was established to contribute to knowledge about metyrosine medication in patients with 22q11.2 DS and psychosis. Methods: A case study was established including a woman with intellectual disability, 22q11.2 DS, and psychosis. Metyrosine medication was implemented, as conventional anti-psychotic medication was unsuccessful. Results: Effect of metyrosine medication included both psychotic symptom relief with decreased aggressive behaviour. Adjunctive milieu therapy contributed to compliance. Conclusion: For patients with 22q11.2 DS and psychosis, metyrosine medication may prove effective. However, there are significant ethical dilemmas related to metyrosine medication for psychotic symptoms. (As Provided). |
Anmerkungen | Routledge. Available from: Taylor & Francis, Ltd. 530 Walnut Street Suite 850, Philadelphia, PA 19106. Tel: 800-354-1420; Tel: 215-625-8900; Fax: 215-207-0050; Web site: http://www.tandf.co.uk/journals |
Erfasst von | ERIC (Education Resources Information Center), Washington, DC |
Update | 2020/1/01 |